Annual ROE
105.06%
-887.32%-89.41%
December 31, 2023
Summary
- As of February 8, 2025, KPTI annual return on equity is 105.06%, with the most recent change of -887.32% (-89.41%) on December 31, 2023.
- During the last 3 years, KPTI annual ROE has risen by +496.35% (+126.85%).
- KPTI annual ROE is now -89.41% below its all-time high of 992.38%, reached on December 31, 2022.
Performance
KPTI ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly ROE
58.62%
-8.27%-12.36%
September 30, 2024
Summary
- As of February 8, 2025, KPTI quarterly return on equity is 58.62%, with the most recent change of -8.27% (-12.36%) on September 30, 2024.
- Over the past year, KPTI quarterly ROE has dropped by -8.27% (-12.36%).
- KPTI quarterly ROE is now -88.20% below its all-time high of 496.77%, reached on September 30, 2013.
Performance
KPTI Quarterly ROE Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
ROE Formula
ROE = Net Income
Shareholders Equity ✕ 100%
Shareholders Equity ✕ 100%
KPTI ROE Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -89.4% | -12.4% |
| 3 y3 years | +126.8% | -85.9% |
| 5 y5 years | +192.1% | +134.6% |
KPTI ROE Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -89.4% | at low | -75.5% | at low |
| 5 y | 5-year | -89.4% | +126.8% | -85.9% | +108.0% |
| alltime | all time | -89.4% | +126.8% | -88.2% | +108.0% |
Karyopharm Therapeutics ROE History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | 58.62%(-12.4%) |
| Jun 2024 | - | 66.89%(-45.5%) |
| Mar 2024 | - | 122.76%(-24.3%) |
| Dec 2023 | 105.06%(-89.4%) | 162.14%(-32.3%) |
| Sep 2023 | - | 239.46%(+15.6%) |
| Jun 2023 | - | 207.18%(+4.4%) |
| Mar 2023 | - | 198.49%(+7.0%) |
| Dec 2022 | 992.38%(+537.2%) | 185.54%(+120.9%) |
| Sep 2022 | - | 84.00%(-17.9%) |
| Jun 2022 | - | 102.26%(-12.0%) |
| Mar 2022 | - | 116.25%(-23.1%) |
| Dec 2021 | 155.75%(-139.8%) | 151.13%(-63.7%) |
| Sep 2021 | - | 416.20%(-156.6%) |
| Jun 2021 | - | -735.49%(+186.2%) |
| Mar 2021 | - | -256.97%(+25.7%) |
| Dec 2020 | -391.29%(+128.3%) | -204.44%(-0.7%) |
| Sep 2020 | - | -205.88%(+6.1%) |
| Jun 2020 | - | -194.00%(-0.2%) |
| Mar 2020 | - | -194.31%(-3.3%) |
| Dec 2019 | -171.36%(+50.1%) | -200.97%(+18.7%) |
| Sep 2019 | - | -169.25%(+21.0%) |
| Jun 2019 | - | -139.91%(+6.5%) |
| Mar 2019 | - | -131.36%(+16.7%) |
| Dec 2018 | -114.13% | -112.53%(+6.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2018 | - | -106.06%(+11.7%) |
| Jun 2018 | - | -94.99%(-7.3%) |
| Mar 2018 | - | -102.44%(+17.2%) |
| Dec 2017 | -88.43%(+45.5%) | -87.39%(+16.0%) |
| Sep 2017 | - | -75.36%(+6.3%) |
| Jun 2017 | - | -70.87%(+0.6%) |
| Mar 2017 | - | -70.44%(+10.3%) |
| Dec 2016 | -60.77%(+4.2%) | -63.85%(+4.8%) |
| Sep 2016 | - | -60.93%(+4.2%) |
| Jun 2016 | - | -58.50%(+9.8%) |
| Mar 2016 | - | -53.26%(+3.5%) |
| Dec 2015 | -58.34%(+39.2%) | -51.45%(+5.3%) |
| Sep 2015 | - | -48.84%(+1.9%) |
| Jun 2015 | - | -47.93%(+7.2%) |
| Mar 2015 | - | -44.71%(+2.1%) |
| Dec 2014 | -41.90%(-21.6%) | -43.79%(-13.7%) |
| Sep 2014 | - | -50.75%(-12.9%) |
| Jun 2014 | - | -58.25%(-21.5%) |
| Mar 2014 | - | -74.18%(-23.9%) |
| Dec 2013 | -53.44%(-193.8%) | -97.54%(-119.6%) |
| Sep 2013 | - | 496.77%(-491.2%) |
| Jun 2013 | - | -126.97%(-362.5%) |
| Mar 2013 | - | 48.37%(+71.3%) |
| Dec 2012 | 56.99%(-30.1%) | 28.24% |
| Dec 2011 | 81.50% | - |
FAQ
- What is Karyopharm Therapeutics annual return on equity?
- What is the all time high annual ROE for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics annual ROE year-on-year change?
- What is Karyopharm Therapeutics quarterly return on equity?
- What is the all time high quarterly ROE for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly ROE year-on-year change?
What is Karyopharm Therapeutics annual return on equity?
The current annual ROE of KPTI is 105.06%
What is the all time high annual ROE for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual return on equity is 992.38%
What is Karyopharm Therapeutics annual ROE year-on-year change?
Over the past year, KPTI annual return on equity has changed by -887.32% (-89.41%)
What is Karyopharm Therapeutics quarterly return on equity?
The current quarterly ROE of KPTI is 58.62%
What is the all time high quarterly ROE for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly return on equity is 496.77%
What is Karyopharm Therapeutics quarterly ROE year-on-year change?
Over the past year, KPTI quarterly return on equity has changed by -8.27% (-12.36%)